Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

References

• Hayes AJ, Bakand S. Toxicological perspectives of inhaled therapeutics and nanoparticles. Expert Opin Drug Metab Toxicol. 2014;10(7):933–947. doi:10.1517/17425255.2014.916276
   PubMed Web of Science ®Google Scholar
• Hye T, Moinuddin SM, Sarkar T, Nguyen T, Saha D, Ahsan F. An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opin Drug Delivery. 2023;20(3):335–348. doi:10.1080/17425247.2023.2175814
   PubMed Web of Science ®Google Scholar
• Forest V, Pourchez J. Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 2022;183:114173.
   PubMed Web of Science ®Google Scholar
• Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A review of non-invasive drug delivery through respiratory routes. Pharmaceutics. 2022;14:9. doi:10.3390/pharmaceutics14091974
   Web of Science ®Google Scholar
• Kamat S, Kumari M, Jayabaskaran C. Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2. J Cont Rel. 2021;338:813–836. doi:10.1016/j.jconrel.2021.08.046
   PubMed Web of Science ®Google Scholar
• Xi J, Longest PW, Martonen TB. Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. J Appl Physiol. 2008;104(6):1761–1777. doi:10.1152/japplphysiol.01233.2007
   PubMed Web of Science ®Google Scholar
• Sreedharan S, Zouganelis G, Drake SJ, Tripathi G, Kermanizadeh A. Nanomaterial-induced toxicity in pathophysiological models representative of individuals with pre-existing medical conditions. J Toxicol Env Heal B. 2023;26(1):1–27. doi:10.1080/10937404.2022.2153456
   Google Scholar
• Bock S, Rades T, Rantanen J, Scherließ R. Additive manufacturing in respiratory sciences - Current applications and future prospects. Adv. Drug Delivery Rev. 2022;186:114341. doi:10.1016/j.addr.2022.114341
   PubMed Web of Science ®Google Scholar
• Mrsny RJ. Lessons from nature: ”Pathogen-Mimetic” systems for mucosal nano-medicines. Adv Drug Deliv Rev. 2009;61(2):172–192.
   PubMed Web of Science ®Google Scholar
• Nho R. Pathological effects of nano-sized particles on the respiratory system. Nanomedicine. 2020;29:102242. doi:10.1016/j.nano.2020.102242
   PubMed Web of Science ®Google Scholar
• Xing Y, Lu P, Xue Z, et al. Nano-strategies for improving the bioavailability of inhaled pharmaceutical formulations. Mini Rev Med Chem. 2020;20(13):1258–1271. doi:10.2174/1389557520666200509235945
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li Y, Chai X, et al. Interaction of pulmonary surfactant with silica and polycyclic aromatic hydrocarbons: implications for respiratory health. Chemosphere. 2019;222:603–610. doi:10.1016/j.chemosphere.2019.02.002
   PubMed Web of Science ®Google Scholar
• Seyfoori A, Shokrollahi Barough M, Mokarram P, et al. Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (VARID). Int J Mol Sci. 2021;22:13. doi:10.3390/ijms22136937
   Web of Science ®Google Scholar
• Xu Y, Parra-Ortiz E, Wan F, et al. Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant. J Colloid Interface Sci. 2023;633:511–525. doi:10.1016/j.jcis.2022.11.059
   PubMed Web of Science ®Google Scholar
• Zhao J, Su J, Qin L, Zhang X, Mao S. Exploring the influence of inhaled liposome membrane fluidity on its interaction with pulmonary physiological barriers. Biomater Sci. 2020;8(23):6786–6797. doi:10.1039/D0BM01529F
   PubMed Web of Science ®Google Scholar
• Ali ME, McConville JT, Lamprecht A. Pulmonary delivery of anti-inflammatory agents. Expert Opin Drug Deliv. 2015;12(6):929–945. doi:10.1517/17425247.2015.993968
   PubMed Web of Science ®Google Scholar
• Renwick LC, Donaldson K, Clouter A. Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol Appl Pharmacol. 2001;172(2):119–127. doi:10.1006/taap.2001.9128
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wong CYJ, Gholizadeh H, et al. Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model. Int J Pharm. 2023;635:122667. doi:10.1016/j.ijpharm.2023.122667
   PubMedGoogle Scholar
• Gradon L, Orlicki D, Podgorski A. Deposition and retention of ultrafine aerosol particles in the human respiratory system. Normal and pathological cases. Int J Occup Saf Ergon. 2000;6(2):189–207. doi:10.1080/10803548.2000.11076451
   PubMedGoogle Scholar
• Stone V, Johnston H, Clift MJ. Air pollution, ultrafine and nanoparticle toxicology: cellular and molecular interactions. IEEE Trans NanoBiosci. 2007;6(4):331–340. doi:10.1109/TNB.2007.909005
   PubMed Web of Science ®Google Scholar
• Kwok PC, Tunsirikongkon A, Glover W, Chan HK. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm Res. 2011;28(4):788–796. doi:10.1007/s11095-010-0332-2
   PubMed Web of Science ®Google Scholar
• Poh TY, Ali N, Mac Aogáin M, et al. Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives. Part Fibre Toxicol. 2018;15(1):46.
   PubMedGoogle Scholar
• Wang W, Huang Z, Huang Y, et al. Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches. Adv. Drug Delivery Rev. 2022;185:114309. doi:10.1016/j.addr.2022.114309
   PubMed Web of Science ®Google Scholar
• Fornaguera C, Llinas M, Solans C, Caldero G. Design and in vitro evaluation of biocompatible dexamethasone-loaded nanoparticle dispersions, obtained from nano-emulsions, for inhalatory therapy. Colloids Surf B Biointerfaces. 2015;125:58–64. doi:10.1016/j.colsurfb.2014.11.006
   PubMed Web of Science ®Google Scholar
• Ziaei E, Emami J, Rezazadeh M, Kazemi M. Pulmonary delivery of docetaxel and celecoxib by PLGA porous microparticles for their synergistic effects against lung cancer. Anticancer Agents Med Chem. 2022;22(5):951–967. doi:10.2174/1871520621666210811111152
   PubMed Web of Science ®Google Scholar
• Rashid J, Alobaida A, Al-Hilal TA, et al. Repurposing rosiglitazone, a PPAR-gamma agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. J Control Release. 2018;280:113–123.
   PubMed Web of Science ®Google Scholar
• Rasul RM, Tamilarasi Muniandy M, Zakaria Z, et al. A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. Carbohydr Polym. 2020;250:116800.
   PubMed Web of Science ®Google Scholar
• Paul P, Sengupta S, Mukherjee B, Shaw TK, Gaonkar RH, Debnath MC. Chitosan-coated nanoparticles enhanced lung pharmacokinetic profile of voriconazole upon pulmonary delivery in mice. Nanomedicine (Lond). 2018;13(5):501–520. doi:10.2217/nnm-2017-0291
   PubMed Web of Science ®Google Scholar
• Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol. 2005;57(7):851–860. doi:10.1211/0022357056334
   PubMed Web of Science ®Google Scholar
• Yoo D, Guk K, Kim H, Khang G, Wu D, Lee D. Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int J Pharm. 2013;450(1–2):87–94. doi:10.1016/j.ijpharm.2013.04.028
   PubMed Web of Science ®Google Scholar
• Satta S, Shahabipour F, Gao W, et al. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants. Theranostics. 2022;12(10):4779–4790. doi:10.7150/thno.72339
   PubMed Web of Science ®Google Scholar
• LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Cont Rel. 2022;345:819–831. doi:10.1016/j.jconrel.2022.03.046
   PubMed Web of Science ®Google Scholar
• Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7–22. doi:10.1016/j.ejpb.2013.08.013
   PubMed Web of Science ®Google Scholar
• Nahar K, Absar S, Patel B, Ahsan F. Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature. Int J Pharm. 2014;464(1–2):185–195. doi:10.1016/j.ijpharm.2014.01.007
   PubMed Web of Science ®Google Scholar
• Rashid J, Nahar K, Raut S, Keshavarz A, Ahsan F. Fasudil and DETA NONOate, loaded in a peptide-modified liposomal carrier, Slow PAH progression upon pulmonary delivery. Mol Pharm. 2018;15(5):1755–1765. doi:10.1021/acs.molpharmaceut.7b01003
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Kuzmov A, Taratula O, Pine SR, Minko T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 2019;9(26):8362–8376. doi:10.7150/thno.39816
   PubMed Web of Science ®Google Scholar
• Jiang Z, Ma Y, Guo X, et al. Sustainable production of lignin micro-/nano-particles (LMNPs) from biomass: influence of the type of biomass on their self-assembly capability and physicochemical properties. J Hazard Mater. 2021;403:123701. doi:10.1016/j.jhazmat.2020.123701
   PubMed Web of Science ®Google Scholar
• Sakellari GI, Zafeiri I, Batchelor H, Spyropoulos F. Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active. Food Hydrocoll Health. 2021;2021:1.
   Google Scholar
• Khan I, Hussein S, Houacine C, et al. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers. Int J Pharm. 2021;598:120376. doi:10.1016/j.ijpharm.2021.120376
   PubMedGoogle Scholar
• Prasanna P, Rathee S, Upadhyay A, Sulakshana S. Nanotherapeutics in the treatment of acute respiratory distress syndrome. Life Sci. 2021;276:119428. doi:10.1016/j.lfs.2021.119428
   PubMed Web of Science ®Google Scholar
• Li H, Sun J, Zhu H, et al. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(2):e1670. doi:10.1002/wnan.1670
   PubMedGoogle Scholar
• Halevas E, Mavroidi B, Kokotidou C, et al. Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery. J Drug Deliv Sci Technol. 2022;75:103625. doi:10.1016/j.jddst.2022.103625
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Ryan GM, et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release. 2014;183:18–26. doi:10.1016/j.jconrel.2014.03.012
   PubMed Web of Science ®Google Scholar
• Zamborlin A, Ermini ML, Summa M, et al. The fate of intranasally instilled silver nanoarchitectures. Nano Lett. 2022;22(13):5269–5276. doi:10.1021/acs.nanolett.2c01180
   PubMed Web of Science ®Google Scholar
• Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials. 2009;30(20):3476–3485. doi:10.1016/j.biomaterials.2009.03.010
   PubMed Web of Science ®Google Scholar
• Hindi KM, Ditto AJ, Panzner MJ, et al. The antimicrobial efficacy of sustained release silver-carbene complex-loaded L-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials. 2009;30(22):3771–3779. doi:10.1016/j.biomaterials.2009.03.044
   PubMed Web of Science ®Google Scholar
• Javed H, Shah SNH, Iqbal FM, Javed N, Saeed B. A hematological and histopathological study on diphenhydramine nasal nano-gel and nano-emulgel for the management of allergic rhinitis in animal model. AAPS Pharm Sci Tech. 2023;24(2):55. doi:10.1208/s12249-023-02515-w
   PubMed Web of Science ®Google Scholar
• Li Y, Han M, Liu T, Cun D, Fang L, Yang M. Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator. Carbohydr Polym. 2017;172:197–204. doi:10.1016/j.carbpol.2017.05.020
   PubMed Web of Science ®Google Scholar
• Yue P, Zhou W, Huang G, et al. Nanocrystals based pulmonary inhalation delivery system: advance and challenge. Drug Deliv. 2022;29(1):637–651. doi:10.1080/10717544.2022.2039809
   PubMed Web of Science ®Google Scholar
• Costabile G, Provenzano R, Azzalin A, et al. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection. Nanomedicine. 2020;23:102113. doi:10.1016/j.nano.2019.102113
   PubMed Web of Science ®Google Scholar
• Ju Y, Hu Y, Yang P, Xie X, Fang B. Extracellular vesicle-loaded hydrogels for tissue repair and regeneration. Mater Today Bio. 2023;2023:18.
   Google Scholar
• Popowski KD, Moatti A, Scull G, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5(9):2960–2974. doi:10.1016/j.matt.2022.06.012
   PubMedGoogle Scholar
• Han Y, Zhu Y, Youngblood HA, et al. Nebulization of extracellular vesicles: a promising small RNA delivery approach for lung diseases. J Control Release. 2022;352:556–569. doi:10.1016/j.jconrel.2022.10.052
   PubMed Web of Science ®Google Scholar
• Zhai Z, Cui T, Chen J, Mao X, Zhang T. Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment. J Transl Med. 2023;21(1). doi:10.1186/s12967-023-04729-9
   Web of Science ®Google Scholar
• Liu C, Xi L, Liu Y, et al. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment. ACS Nano. 2023;17(12):11626–11644. doi:10.1021/acsnano.3c02075
   PubMed Web of Science ®Google Scholar
• Rothen DA, Krenger PS, Nonic A, et al. Intranasal administration of a virus like particles‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern. Allergy. 2022;77(8):2446–2458. doi:10.1111/all.15311
   PubMed Web of Science ®Google Scholar
• Wang Z, Popowski KD, Zhu D, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng. 2022;6(7):791–805. doi:10.1038/s41551-022-00902-5
   PubMed Web of Science ®Google Scholar
• Zakaria MY, El-Halim SM A, Beshay BY, Zaki I, Abourehab MAS. ‘Poly phenolic phytoceutical loaded nano-bilosomes for enhanced caco-2 cell permeability and SARS-CoV 2 antiviral activity’: in-vitro and insilico studies. Drug Deliv. 2023;30(1):2162157. doi:10.1080/10717544.2022.2162157
   PubMed Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomo C, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2016;60(1):6–13. doi:10.1128/AAC.01802-15
   PubMed Web of Science ®Google Scholar
• Liu Q, Guan J, Song R, Zhang X, Mao S. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants. Acta Biomater. 2022;140:76–87. doi:10.1016/j.actbio.2021.11.034
   PubMed Web of Science ®Google Scholar
• Raine RI. Technology in respiratory medicine. Cont Med Educ. 2003;16(4):200.
   Google Scholar
• Barthold S, Kunschke N, Murgia X, Loretz B, Carvalho-Wodarz CS, Lehr CM. Overview of inhaled nanopharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2023;36(3):144–151. doi:10.1089/jamp.2023.29089.sb
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou C, Zhang W, et al. Effect and mechanism of PINK1/parkin-mediated mitochondrial autophagy in rat lung injury induced by nano lanthanum oxide. Nanomaterials. 2022;12:15.
   Web of Science ®Google Scholar
• Basu S, Kabi P, Chaudhuri S, Saha A. Insights on drying and precipitation dynamics of respiratory droplets from the perspective of COVID-19. Phys Fluids. 2020;32(12):123317. doi:10.1063/5.0037360
   PubMed Web of Science ®Google Scholar
• Fdez-Arroyabe P, Salcines C, Kassomenos P, Santurtún A, Petäjä T. Electric charge of atmospheric nanoparticles and its potential implications with human health. Sci Total Environ. 2022;808:152106. doi:10.1016/j.scitotenv.2021.152106
   PubMed Web of Science ®Google Scholar
• Phan TH, Shi H, Denes CE, et al. Advanced pathophysiology mimicking lung models for accelerated drug discovery. Biomater Res. 2023;27(1):35. doi:10.1186/s40824-023-00366-x
   PubMedGoogle Scholar
• Wang H, Wu L, Sun X. Intratracheal delivery of nano- and microparticles and hyperpolarized gases: a promising strategy for the imaging and treatment of respiratory disease. Chest. 2020;157(6):1579–1590. doi:10.1016/j.chest.2019.11.036
   PubMed Web of Science ®Google Scholar
• Blank F, Fytianos K, Seydoux E, et al. Interaction of biomedical nanoparticles with the pulmonary immune system. J Nanobiotechnology. 2017;15(1):6. doi:10.1186/s12951-016-0242-5
   PubMedGoogle Scholar
• Ruenraroengsak P, Novak P, Berhanu D, et al. Respiratory epithelial cytotoxicity and membrane damage (holes) caused by amine-modified nanoparticles. Nanotoxicology. 2012;6(1):94–108. doi:10.3109/17435390.2011.558643
   PubMed Web of Science ®Google Scholar
• Doryab A, Taskin MB, Stahlhut P, et al. A bioinspired in vitro lung model to study particokinetics of nano-/microparticles under cyclic stretch and air-liquid interface conditions. Front Bioeng Biotechnol. 2021;9:616830. doi:10.3389/fbioe.2021.616830
   PubMed Web of Science ®Google Scholar
• Bessa MJ, Brandão F, Rosário F, et al. Assessing the in vitro toxicity of airborne (nano)particles to the human respiratory system: from basic to advanced models. J Toxicol Env Heal B. 2023;26(2):67–96. doi:10.1080/10937404.2023.2166638
   Google Scholar
• Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol. 2010;7:2. doi:10.1186/1743-8977-7-2
   PubMed Web of Science ®Google Scholar
• Kurbatova P, Bessonov N, Volpert V, et al. Model of mucociliary clearance in cystic fibrosis lungs. J Theor Biol. 2015;372:81–88. doi:10.1016/j.jtbi.2015.02.023
   PubMed Web of Science ®Google Scholar
• Bustamante-Marin XM, Ostrowski LE. Cilia and mucociliary clearance. Cold Spring Harbor Perspect. Biol. 2017;9(4):a028241. doi:10.1101/cshperspect.a028241
   PubMed Web of Science ®Google Scholar
• Newman SP. Drug delivery to the lungs: challenges and opportunities. Therap Deliv. 2017;8(8):647–661. doi:10.4155/tde-2017-0037
   PubMed Web of Science ®Google Scholar
• Anderson CF, Grimmett ME, Domalewski CJ, Cui H. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:1.
   Web of Science ®Google Scholar
• Kiyono H, Azegami T. The mucosal immune system: from dentistry to vaccine development. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(8):423–439. doi:10.2183/pjab.91.423
   PubMed Web of Science ®Google Scholar
• Ardain A, Marakalala MJ, Leslie A. Tissue-resident innate immunity in the lung. Immunology. 2020;159(3):245–256. doi:10.1111/imm.13143
   PubMed Web of Science ®Google Scholar
• Gosens I, Cassee FR, Zanella M, et al. Organ burden and pulmonary toxicity of nano-sized copper (II) oxide particles after short-term inhalation exposure. Nanotoxicology. 2016;10(8):1084–1095. doi:10.3109/17435390.2016.1172678
   PubMed Web of Science ®Google Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed--characterizing the fate of inhaled pharmaceuticals. J Aero Med Pulm Drug Deliv. 2010;23:S71–87.
   PubMed Web of Science ®Google Scholar
• Mühlfeld C, Rothen-Rutishauser B, Blank F, Vanhecke D, Ochs M, Gehr P. Interactions of nanoparticles with pulmonary structures and cellular responses. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L817–829. doi:10.1152/ajplung.00442.2007
   PubMed Web of Science ®Google Scholar
• Truzzi E, Nascimento TL, Iannuccelli V, et al. In vivo biodistribution of respirable solid lipid nanoparticles surface-decorated with a mannose-based surfactant: a promising tool for pulmonary tuberculosis treatment? Nanomaterials. 2020;10:3.
   Web of Science ®Google Scholar
• Shah RM, Rajasekaran D, Ludford-Menting M, Eldridge DS, Palombo EA, Harding IH. Transport of stearic acid-based solid lipid nanoparticles (SLNs) into human epithelial cells. Colloids Surf B. 2016;140:204–212. doi:10.1016/j.colsurfb.2015.12.029
   PubMed Web of Science ®Google Scholar
• Guagliardo R, Pérez-Gil J, De Smedt S, Raemdonck K. Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins. J Cont Rel. 2018;291:116–126. doi:10.1016/j.jconrel.2018.10.012
   PubMed Web of Science ®Google Scholar
• Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev. 2008;60(8):929–938. doi:10.1016/j.addr.2007.11.007
   PubMed Web of Science ®Google Scholar
• Soto KF, Murr LE, Garza KM. Cytotoxic responses and potential respiratory health effects of carbon and carbonaceous nanoparticulates in the Paso del Norte airshed environment. Int J Environ Res Public Health. 2008;5(1):12–25. doi:10.3390/ijerph5010012
   PubMedGoogle Scholar
• Cena LG, Chisholm WP, Keane MJ, Chen BT. A field study on the respiratory deposition of the nano-sized fraction of mild and stainless steel welding fume metals. J Occup Environ Hyg. 2015;12(10):721–728. doi:10.1080/15459624.2015.1043055
   PubMed Web of Science ®Google Scholar
• Bierkandt FS, Leibrock L, Wagener S, Laux P, Luch A. The impact of nanomaterial characteristics on inhalation toxicity. Toxicol Res (Camb). 2018;7(3):321–346.
   PubMed Web of Science ®Google Scholar
• Song S, Ding L, Liu G, et al. The protective effects of baicalin for respiratory diseases: an update and future perspectives. Front Pharmacol. 2023;14:1129817.
   PubMed Web of Science ®Google Scholar
• Lee SH, Wang TY, Hong JH, Cheng TJ, Lin CY. NMR-based metabolomics to determine acute inhalation effects of nano- and fine-sized ZnO particles in the rat lung. Nanotoxicology. 2016;10(7):924–934.
   PubMed Web of Science ®Google Scholar
• Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr Respir Rev. 2007;8(1):62–66.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu Y, Zhao B, et al. Amorphous silica nanoparticles caused lung injury through the induction of epithelial apoptosis via ROS/Ca(2+)/DRP1-mediated mitochondrial fission signaling. Nanotoxicology. 2022;16:6–8.
   Web of Science ®Google Scholar
• Sayers BC, Germolec DR, Walker NJ, et al. Respiratory toxicity and immunotoxicity evaluations of microparticle and nanoparticle C60 fullerene aggregates in mice and rats following nose-only inhalation for 13 weeks. Nanotoxicology. 2016;10(10):1458–1468.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhang G, Xie M, et al. Softness enhanced macrophage-mediated therapy of inhaled apoptotic-cell-inspired nanosystems for acute lung injury. J Nanobiotechnology. 2023;21(1):172.
   PubMed Web of Science ®Google Scholar
• Wei T, Tang M. Biological effects of airborne fine particulate matter (PM(2.5)) exposure on pulmonary immune system. Environ Toxicol Pharmacol. 2018;60:195–201.
   PubMed Web of Science ®Google Scholar
• Yu Y, Pan Y, Chang B, Zhao X, Qu K, Song Y. Silica nanoparticles induce pulmonary damage in rats via VEGFC/D-VEGFR3 signaling-mediated lymphangiogenesis and remodeling. Toxicology. 2023;493:153552.
   PubMed Web of Science ®Google Scholar
• Lee SH, Tang CH, Lin WY, et al. LC-MS-based lipidomics to examine acute rat pulmonary responses after nano- and fine-sized ZnO particle inhalation exposure. Nanotoxicology. 2018;12(5):439–452.
   PubMed Web of Science ®Google Scholar
• Meneses J, González-Durruthy M, Fernandez-de-Gortari E, Toropova AP, Toropov AA, Alfaro-Moreno E. A Nano-QSTR model to predict nano-cytotoxicity: an approach using human lung cells data. Part Fibre Toxicol. 2023;20(1):21.
   PubMed Web of Science ®Google Scholar
• Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems. Polymers. 2023;15:7.
   Web of Science ®Google Scholar
• Huang X, Li C, Wei T, et al. Oropharyngeal aspirated Ag/TiO2 nanohybrids: transformation, distribution and toxicity. Science of the Total Environment. 2024;2024:908.
   Google Scholar
• Tomita Y, Rikimaru-Kaneko A, Hashiguchi K, Shirotake S. Effect of anionic and cationic n-butylcyanoacrylate nanoparticles on NO and cytokine production in Raw264.7 cells. Immuno and Immunotoxicology. 2011;33(4):730–737. doi:10.3109/08923973.2011.565345
   PubMed Web of Science ®Google Scholar
• Xu Y, Zheng Y, Ding X, et al. PEGylated pH-responsive peptide-mRNA nano self-assemblies enhance the pulmonary delivery efficiency and safety of aerosolized mRNA. Drug Delivery. 2023;30(1):2219870. doi:10.1080/10717544.2023.2219870
   PubMed Web of Science ®Google Scholar
• Doroudian M, ON A, Mac Loughlin R, Prina-Mello A, Volkov Y, Donnelly SC. Nanotechnology in pulmonary medicine. Curr Opin Pharmacol. 2021;56:85–92. doi:10.1016/j.coph.2020.11.002
   PubMed Web of Science ®Google Scholar
• Omlor AJ, Nguyen J, Bals R, Dinh QT. Nanotechnology in respiratory medicine. Respir Res. 2015;16(1):64. doi:10.1186/s12931-015-0223-5
   PubMedGoogle Scholar
• Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly SC. Nanotechnology based therapeutics for lung disease. Thorax. 2019;74(10):965–976. doi:10.1136/thoraxjnl-2019-213037
   PubMed Web of Science ®Google Scholar
• Shim MK, Song SK, Jeon SI, Hwang KY, Kim K. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opin Drug Deliv. 2022;19(6):641–652. doi:10.1080/17425247.2022.2081683
   PubMed Web of Science ®Google Scholar
• Lee HY, Mohammed KA, Nasreen N. Nanoparticle-based targeted gene therapy for lung cancer. Am J Can Res. 2016;6(5):1118–1134.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li S, Wang X, et al. Smart transformable nanomedicines for cancer therapy. Biomaterials. 2021;271:120737. doi:10.1016/j.biomaterials.2021.120737
   PubMed Web of Science ®Google Scholar
• Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108–121. doi:10.1016/j.jconrel.2016.11.015
   PubMed Web of Science ®Google Scholar
• Alshammari MK, Almomen EY, Alshahrani KF, et al. Nano-enabled strategies for the treatment of lung cancer: potential bottlenecks and future perspectives. Biomedicines. 2023;11(2). doi:10.3390/biomedicines11020473
   Web of Science ®Google Scholar
• Yang SJ, Huang CH, Wang CH, Shieh MJ, Chen KC. The synergistic effect of hyperthermia and chemotherapy in magnetite nanomedicine-based lung cancer treatment. Int j Nanomed. 2020;15:10331–10347. doi:10.2147/IJN.S281029
   PubMed Web of Science ®Google Scholar
• Guan S, Munder A, Hedtfeld S, et al. Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019;14(3):287–297. doi:10.1038/s41565-018-0358-x
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–518. doi:10.1016/j.jconrel.2015.07.024
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171(3):349–357. doi:10.1016/j.jconrel.2013.04.018
   PubMed Web of Science ®Google Scholar
• Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188645. doi:10.1016/j.bbcan.2021.188645
   PubMed Web of Science ®Google Scholar
• Tseng CL, Wu SY, Wang WH, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29(20):3014–3022. doi:10.1016/j.biomaterials.2008.03.033
   PubMed Web of Science ®Google Scholar
• Sadhukha T, Wiedmann TS, Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials. 2013;34(21):5163–5171. doi:10.1016/j.biomaterials.2013.03.061
   PubMed Web of Science ®Google Scholar
• Griesenbach U, Pytel KM, Alton EW. Cystic fibrosis gene therapy in the UK and elsewhere. Hum Gene Ther. 2015;26(5):266–275. doi:10.1089/hum.2015.027
   PubMed Web of Science ®Google Scholar
• Suk JS, Kim AJ, Trehan K, et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release. 2014;178:8–17. doi:10.1016/j.jconrel.2014.01.007
   PubMed Web of Science ®Google Scholar
• Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 2004;15(12):1255–1269. doi:10.1089/hum.2004.15.1255
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release. 2019;296:225–231.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1(1):15025.
   PubMedGoogle Scholar
• Broza YY, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomed. 2013;8(5):785–806. doi:10.2217/nnm.13.64
   PubMed Web of Science ®Google Scholar
• Taylor SL, Leong LEX, Choo JM, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol. 2018;141(1):94–103.e115. doi:10.1016/j.jaci.2017.03.044
   PubMed Web of Science ®Google Scholar
• Plaza V, Crespo A, Giner J, et al. Inflammatory asthma phenotype discrimination using an electronic nose breath analyzer. J Investig Allergol Clin Immunol. 2015;25(6):431–437.
   PubMed Web of Science ®Google Scholar
• Craparo EF, Drago SE, Quaglia F, Ungaro F, Cavallaro G. Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation. Drug Delivery Transl Res. 2022;12(8):1859–1872. doi:10.1007/s13346-021-01102-5
   PubMed Web of Science ®Google Scholar
• Xu J, Xiao N, Zhou D, Xie L. Disease tolerance: a protective mechanism of lung infections. Front Cell Infect Microbiol. 2023;13:1037850. doi:10.3389/fcimb.2023.1037850
   PubMed Web of Science ®Google Scholar
• Pettigrew MM, Tanner W, Harris AD. The lung microbiome and pneumonia. J Infect Dis. 2021;223(12 Suppl 2):S241–s245. doi:10.1093/infdis/jiaa702
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Wu J, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1958–1964.
   PubMed Web of Science ®Google Scholar
• Vij N, Chandramani-Shivalingappa P, Van Westphal C, Hole R, Bodas M. Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis. Am J Physiol Cell Physiol. 2018;314(1):C73–C87. doi:10.1152/ajpcell.00110.2016
   PubMed Web of Science ®Google Scholar
• Costabile G, Mitidieri E, Visaggio D, et al. Boosting lung accumulation of gallium with inhalable nano-embedded microparticles for the treatment of bacterial pneumonia. Int J Pharm. 2022;629:122400. doi:10.1016/j.ijpharm.2022.122400
   PubMedGoogle Scholar
• Costa-Gouveia J, Pancani E, Jouny S, et al. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci Rep. 2017;7(1):5390. doi:10.1038/s41598-017-05453-3
   PubMed Web of Science ®Google Scholar
• Huck BC, Thiyagarajan D, Bali A, et al. Nano-in-microparticles for aerosol delivery of antibiotic-loaded, fucose-derivatized, and macrophage-targeted liposomes to combat mycobacterial infections: in vitro deposition, pulmonary barrier interactions, and targeted delivery. Adv. Healthcare Mater. 2022;11(11):e2102117. doi:10.1002/adhm.202102117
   Web of Science ®Google Scholar
• Tsoras AN, Champion JA. Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications. Annu Rev Chem Biomol. 2019;10:337–359. doi:10.1146/annurev-chembioeng-060718-030347
   PubMed Web of Science ®Google Scholar
• Loo CY, Lee WH, Zhou QT. Recent advances in inhaled nanoformulations of vaccines and therapeutics targeting respiratory viral infections. Pharm Res. 2023;40(5):1015–1036.
   PubMed Web of Science ®Google Scholar
• Zhong W, Zhang X, Zeng Y, Lin D, Wu J. Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 2021;14(7):2067–2089.
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–522. doi:10.1038/nature12978
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.
   PubMed Web of Science ®Google Scholar
• Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019;10:22. doi:10.3389/fimmu.2019.00022
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–1360. doi:10.1126/science.aar7112
   PubMed Web of Science ®Google Scholar
• Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol. 2019;10:8. doi:10.3389/fimmu.2019.00008
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: clinical experience and future directions. Pharmacol Ther. 2015;153:1–9. doi:10.1016/j.pharmthera.2015.05.004
   PubMed Web of Science ®Google Scholar
• Maarof NNN, Abdulmalek E, Fakurazi S, Rahman MBA. Biodegradable carbonate apatite nanoparticle as a delivery system to promote afatinib delivery for non-small cell lung cancer treatment. Pharmaceutics. 2022;14(6):1230. doi:10.3390/pharmaceutics14061230
   PubMed Web of Science ®Google Scholar
• Saleh T, Shojaosadati SA. Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother. 2016;12(7):1863–1875. doi:10.1080/21645515.2016.1147635
   PubMed Web of Science ®Google Scholar
• Knight FC, Gilchuk P, Kumar A, et al. Mucosal Immunization with a pH-responsive nanoparticle vaccine induces protective CD8(+) lung-resident memory T cells. ACS Nano. 2019;13(10):10939–10960. doi:10.1021/acsnano.9b00326
   PubMed Web of Science ®Google Scholar
• Ding B, Zheng P, Jiang F, et al. MnO(x) nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect. Angewan Chem. 2020;59(38):16381–16384. doi:10.1002/anie.202005111
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Chen X, et al. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. Journal for Immunotherapy of Cancer. 2021;9(8):e003132. doi:10.1136/jitc-2021-003132
   PubMed Web of Science ®Google Scholar
• An M, Liu H. Dissolving microneedle arrays for transdermal delivery of amphiphilic vaccines. Small. 2017;13(26). doi:10.1002/smll.201700164
   Web of Science ®Google Scholar
• Wang S, Gao J, Wang Z. Outer membrane vesicles for vaccination and targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(2):e1523. doi:10.1002/wnan.1523
   PubMed Web of Science ®Google Scholar
• Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nature Nanotechnol. 2020;15(8):646–655. doi:10.1038/s41565-020-0737-y
   PubMed Web of Science ®Google Scholar
• Hussain A, Yang H, Zhang M, et al. mRNA vaccines for COVID-19 and diverse diseases. J Control Release. 2022;345:314–333.
   PubMed Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015. doi:10.1021/acsnano.1c04996
   PubMed Web of Science ®Google Scholar
• Yin Y, Su W, Zhang J, et al. Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19. ACS Nano. 2021;15(9):14347–14359. doi:10.1021/acsnano.1c03252
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi:10.1038/nrd.2017.243
   PubMed Web of Science ®Google Scholar
• Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601. doi:10.1038/s41467-020-16505-0
   PubMed Web of Science ®Google Scholar
• Taina-González L, de la Fuente M. The potential of nanomedicine to unlock the limitless applications of mRNA. Pharmaceutics. 2022;14(2):460. doi:10.3390/pharmaceutics14020460
   PubMed Web of Science ®Google Scholar
• Siva S, Hardcastle N, Kron T, et al. Ventilation/perfusion positron emission tomography--based assessment of radiation injury to lung. Int J Radiat Oncol Biol Phys. 2015;93(2):408–417. doi:10.1016/j.ijrobp.2015.06.005
   PubMed Web of Science ®Google Scholar
• Wu L, Wen X, Wang X, et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging. Theranostics. 2018;8(2):563–574. doi:10.7150/thno.21466
   PubMed Web of Science ®Google Scholar
• Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med. 2013;5(216):216rv214. doi:10.1126/scitranslmed.3005872
   Web of Science ®Google Scholar
• Aghebati-Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235(3):1962–1972. doi:10.1002/jcp.29126
   PubMed Web of Science ®Google Scholar
• Han Z, Tu X, Qiao L, et al. Phototherapy and multimodal imaging of cancers based on perfluorocarbon nanomaterials. J Mater Chem B. 2021;9(34):6751–6769. doi:10.1039/D1TB00554E
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang R, Liu F, et al. (19)F MRI in orthotopic cancer model via intratracheal administration of α(ν)β(3)-targeted perfluorocarbon nanoparticles. Nanomed. 2018;13(20):2551–2562. doi:10.2217/nnm-2018-0051
   PubMed Web of Science ®Google Scholar
• Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomed. 2014;9:1491–1503. doi:10.2147/IJN.S59394
   PubMed Web of Science ®Google Scholar
• Tay ZW, Chandrasekharan P, Zhou XY, Yu E, Zheng B, Conolly S. In vivo tracking and quantification of inhaled aerosol using magnetic particle imaging towards inhaled therapeutic monitoring. Theranostics. 2018;8(13):3676–3687. doi:10.7150/thno.26608
   PubMed Web of Science ®Google Scholar
• Schmieder AH, Caruthers SD, Keupp J, Wickline SA, Lanza GM. Recent Advances in (19) fluorine magnetic resonance imaging with perfluorocarbon emulsions. Engineering (Beijing). 2015;1(4):475–489. doi:10.15302/J-ENG-2015103
   PubMedGoogle Scholar
• Himmelreich U, Weber R, Ramos-Cabrer P, et al. Improved stem cell MR detectability in animal models by modification of the inhalation gas. Mol Imaging. 2005;4(2):104–109. doi:10.1162/15353500200504196
   PubMedGoogle Scholar
• Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. Int J Mol Sci. 2021;22(5). doi:10.3390/ijms22052625
   PubMed Web of Science ®Google Scholar
• Wu L, Liu F, Liu S, Xu X, Liu Z, Sun X. Perfluorocarbons-Based (19)F magnetic resonance imaging in biomedicine. Int J Nanomed. 2020;15:7377–7395. doi:10.2147/IJN.S255084
   PubMed Web of Science ®Google Scholar
• Mizuno T, Mohri K, Nasu S, Danjo K, Okamoto H. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence. J Control Release. 2009;134(2):149–154. doi:10.1016/j.jconrel.2008.11.018
   PubMed Web of Science ®Google Scholar
• R A, Han Z, Wang T, Zhu M, Zhou M, Sun X. Pulmonary delivery of nano-particles for lung cancer diagnosis and therapy: recent advances and future prospects. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;e1933. doi:10.1002/wnan.1933
   PubMed Web of Science ®Google Scholar
• Xu Y, Xiang J, Zhao H, et al. Human amniotic fluid stem cells labeled with up-conversion nanoparticles for imaging-monitored repairing of acute lung injury. Biomaterials. 2016;100:91–100. doi:10.1016/j.biomaterials.2016.05.034
   PubMed Web of Science ®Google Scholar
• Xie X, Zhan C, Wang J, Zeng F, Wu S. An activatable nano-prodrug for treating tyrosine-kinase-inhibitor-resistant non-small cell lung cancer and for optoacoustic and fluorescent imaging. Small. 2020;16(38):e2003451. doi:10.1002/smll.202003451
   PubMed Web of Science ®Google Scholar